Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and DR-TB STAT will host a webinar on 1 August 2018 at 10 am New York / 4pm South Africa / 5pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB.

Activists ask the company to drop the price of bedaquiline in all markets to $32 a month or lower.

Global TB CAB welcomes introduction of safer drug for most South Africans with rifampicin-resistant TB; Other countries and the World Health Organization must now follow.

Advocates call on WHO leadership to ensure rapid development of clear, consolidated guidelines for the diagnosis and treatment of TB.

TB CAB issues a position statement on the use of bedaquiline as part of the preferred regimen for MDR-TB.

Тhe Global TB Community Advisory Board (TB CAB) releases a position paper regarding the optimal design for future evaluation of regimens for the treatment of extensively drug-resistant TB (XDR-TB).

TB advocates urge the Kenyan Division of Leprosy, Tuberculosis and Lung Disease (DLTLD) to introduce a new, simple, and rapid TB test, TB LAM, which detects TB antigens in urine, and is an important tool for detecting TB in certain populations living with HIV.

TB advocates stress the importance of the observational endTB study for expanding access to new treatments for multidrug-resistant TB in Peru.

TB advocates reiterate the important role the Ministry of Health must play in facilitating access to delamanid for Peruvians with multidrug-resistant TB.

TB advocates encourage Danaher, a holdings company that recently acquired Cepheid, to prioritize the continued development of critical Cepheid products for TB.